



Formerly



**SRS/ MEETING
19th / 20th March 2020**

Thursday 19th March 2020

- | | |
|--------------------|--|
| 9.00-9.15 | Welcome |
| 9.15-10.45 | Local Symposium |
| 10.45-11.00 | Coffee |
| 11.00-12.00 | Abstract Presentations |
| 12.00-12.45 | Lunch (Poster Presentations) |
| 12.45-13.15 | Prize Winners Presentations. SUS, SRS(SA), ESSR, Sylvester O'Halloran, |
| 13.15-14.15 | Research Collaboratives – Dragons Den
Submitted by Abstract (Open Dec-Jan) |
| 14.15-14.30 | Coffee (Poster Presentations) |
| 14.30-15.30 | Patey Prize Session 1. |
| 15.30-16.00 | John Farndon Lecture Professor Mike Murphy. |
| 16.00-17.00 | Parallel Presentations
National Institute of Academic Anaesthesia Prize Oral Presentations
Association of Breast Surgery Prize Oral Presentations
Vascular Society Prize Presentations |
| 17.00-17.30 | Annual General Meeting |
| 19.30 | Society Dinner (Ticket holders only) |

Friday 20th March 2020

- 08.00-10.00** Parallel Workshop Sessions
Research Methods Workshop
ICH GCP Training Workshop
Simulation Training for Medical Students Workshop
Research Nurses Workshop
- 10.00-10.15** Coffee
- 10.15-11.15** **Abstract Presentations**
- 11.15-12.15** ASiT symposium
- 12.15-13.15** Med-Tech Foundation symposium
- 13.15-14.00** Lunch (Poster Presentations)
- 14.00-14.30** **Abstract Presentations**
- 14.30-15.30** Patey Prize session 2
- 15.30-16.00** Coffee (Poster Presentations)
- 16.00-16.30** BJS Lecture – Dr. Muriel Brackstone
- 16.30-17.00** Presentation of Prizes

Invited Guest Speakers.



John Farandon Lecture: Professor Mike Murphy

Mike Murphy received his BA in chemistry at Trinity College, Dublin in 1984 and his PhD in Biochemistry at Cambridge University in 1987. After stints in the USA, Zimbabwe, and Ireland he took up a faculty position in the Biochemistry Department at the University of Otago, Dunedin, New Zealand in 1992. In 2001 he moved to the MRC Mitochondrial Biology Unit in Cambridge, UK (then called the MRC Dunn Human Nutrition Unit) where he is a programme leader. Murphy's research focuses on the roles of reactive oxygen species in mitochondrial function and pathology. In particular he has pioneered the targeting of bioactive and probe molecules to mitochondria *in vivo*. This general methodology is now widely used. Prominent mitochondria-targeted compounds are antioxidants, such as MitoQ, which protects against oxidative damage in ischaemia-reperfusion injury. Murphy and Rob Smith developed MitoQ as an oral drug which has been used in two Phase II trials so far. This work established mitochondria as a relevant drug target and opened up the field of mitochondrial pharmacology. The Murphy group has gone on to create MitoSNO, a mitochondria-targeted nitric oxide donor which is now being developed as a potential therapy for cardiac ischaemia-reperfusion injury, and MitoG to treat diabetes. Recently his work has extended to determining the mechanism by which mitochondria produce free radicals during ischaemia-reperfusion injury in heart attack and stroke. Murphy is Professor of Mitochondrial Redox Biology at the University of Cambridge, a Wellcome Trust Investigator, honorary research Professor at the University of Otago, New Zealand, a recipient of the Keilin Medal from the Biochemical Society, an honorary Fellow of the Royal Society of New Zealand and a Fellow of the Academy of Medical Sciences (FMedSci). He has published more than 345 peer reviewed papers, which have garnered more than 39,000 citations and he has an h-index of 106.



BJS Lecturer. Dr. Muriel Brackstone

Dr. Muriel Brackstone is a surgical oncologist in London, Canada and Professor of Surgery and Oncology at the University of Western Ontario. She obtained her Medical Degree and General Surgical Residency at the University of Western Ontario and her fellowship in Breast Surgical Oncology at the University of Toronto. As a practicing surgeon, she obtained her Masters Degree in Epidemiology & Biostatistics followed by a PhD in Clinical Trials (Dept Pathology). She is the Medical Director of London's Breast Care Program and founding Director of the London Tumour Biobank, which is a biospecimen repository and translational research platform for serial imaging, tumour biopsies and blood collection with life-long clinical follow-up data. She is the lead author of national guidelines for the management of locally advanced breast cancer and management of the axilla. She co-founded Canada's only hands-on Oncoplastic Surgery Training Program and has developed the standards for the role of oncoplastic surgery in breast conservation in Canada. She has conducted a number of clinical trials most notably in the neoadjuvant setting, including the role of concurrent neoadjuvant radiation with chemotherapy in breast cancer, the role of probiotics on the inflammation-inducing breast microbiome, hypofractionated radiation in the neoadjuvant setting and its role in immune priming, with an ongoing research program in prone hypofractionated radiation concurrent with immune checkpoint inhibitors. She has over 100 peer reviewed publications with 50 peer reviewed grants to date. Dr. Brackstone is also a practicing general surgeon with four young children.